CoreCap Advisors’s Takeda Pharmaceutical TAK Stock Holding History

CoreCap Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-75	Closed	-$993	–	3295
2024 Q4	$993	Hold	75	–	–	﹤0.01%	2377
2024 Q3	$1.07K	Buy	+75	New	+$1.06K	﹤0.01%	2261
2024 Q2	–	Sell	-75	Closed	-$1.04K	–	2466
2024 Q1	$1.04K	Buy	+75	New	+$1.09K	﹤0.01%	2218
2022 Q4	$1.17K	Buy	+75	New	+$1.05K	﹤0.01%	2024
2022 Q3	–	Sell	-220	Closed	-$3K	–	1904
2022 Q2	$3K	Buy	+220	New	+$3.14K	﹤0.01%	1813
2022 Q1	–	Sell	-727	Closed	-$10K	–	1908
2021 Q4	$10K	Buy	+727	New	+$10.2K	﹤0.01%	1557

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

CoreCap Advisors's TAK Position: Q1 2025 in Review

CoreCap Advisors sold out of Takeda Pharmaceutical (TAK) in Q1 2025, closing a stake of 75 shares — an estimated $993 sold.

CoreCap Advisors first reported a position in TAK in Q4 2021 and held it in 6 quarters. The position peaked at $10K in Q4 2021. 309 funds tracked by Wall St. Rank hold TAK as of Q1 2025.

CoreCap Advisors reported no remaining Takeda Pharmaceutical position as of Q1 2025 after selling out during the quarter.
CoreCap Advisors sold 75 Takeda Pharmaceutical shares in Q1 2025, an estimated $993.
CoreCap Advisors first reported a position in Takeda Pharmaceutical in Q4 2021 and held it in 6 quarters.
CoreCap Advisors's Takeda Pharmaceutical position peaked at $10K in Q4 2021.
309 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2025.

Based on CoreCap Advisors's 13F filing for Q1 2025, filed 9 May 2025.